Beeline Medicines secures $126M from Bain Capital, CPPIB and Bristol Myers to expand immunology pipeline
read at Endpoints ↗DealPositive
Beeline Medicines, a spinout from Bristol Myers Squibb, announced it has received an additional $126 million in financing.
The new capital comes from existing investors Bain Capital and the Canada Pension Plan Investment Board, as well as from Bristol Myers itself, reinforcing their commitment to the company's immunology program.
CEO Saqib Islam said the funding will accelerate development of the pipeline’s immunology candidates, positioning Beeline for future growth and potential partnerships.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers”
read at Endpoints ↗94 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that